Development of target characterization methods for novel cancer markers
Active Awarded Last action
- Contract number
- 75N91020F00026
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $56,499,671
Award facts
- Contract value 100% obligated
- $56,499,671.48 Current and potential, with all options
- Completion date 91% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $17,488,492 | |
| Other Administrative Action | -$1,995,955 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $41,007,134 |
About this award
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. and Federally Funded Research and Development Center contractor, received a $56.5 million cost-plus-fixed-fee delivery order from the National Cancer Institute to develop target characterization methods for novel cancer markers. The contract, awarded September 28, 2020, with an ultimate completion date of May 25, 2027, will be performed at Leidos' Frederick, Maryland facility. No set-aside designation was used for this award. As a specialized FFRDC contractor supporting the National Cancer Institute, Leidos Biomedical Research Inc. brings extensive biomedical research capabilities across medical research, clinical trials, facility management, and advanced technological solutions relevant to cancer research initiatives.
The contract includes three subcontractors supporting distinct technical requirements: Experimental Pathology Laboratories, Inc. provides histology services including tissue processing, paraffin embedding, sectioning, and specialized staining (H&E, IFA, and IHC); Fisher Scientific supplies a cell imaging system procured August 8, 2023; and Terumo BCT Inc. provided capital welding system equipment as of April 20, 2023. These subcontractor contributions support the comprehensive laboratory and analytical infrastructure necessary for developing and characterizing biomarkers to advance cancer research capabilities within the National Cancer Institute's research portfolio.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Experimental Pathology Laboratories, Inc. | $275,000 |
Quick answers
Who was awarded contract 75N91020F00026?
75N91020F00026 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2020.
How much is contract 75N91020F00026 worth?
The government has obligated $56,499,671 on 75N91020F00026.
Is contract 75N91020F00026 an order under another contract?
Yes. 75N91020F00026 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00026 competed?
The extent of competition for 75N91020F00026 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award